1 min read
Add as a preferred source on GoogleFDA Approves Perioperative Durvalumab-Padcev for Cisplatin-Ineligible MIBC
The approval covers perioperative use in patients who cannot receive cisplatin-based chemotherapy.
The U.S. Food and Drug Administration approved perioperative use of durvalumab with Padcev (enfortumab vedotin) for patients with muscle-invasive bladder cancer who cannot receive cisplatin-based chemotherapy.
The combination pairs AstraZeneca’s durvalumab with Padcev from Pfizer and Astellas.
Riza Dagoc
Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.